Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

NCT05444153 · Withdrawn

Last updated 2026-05-28

This study is testing two diabetes medications, semaglutide and empagliflozin, taken as tablets once a day, in adults with type 2 diabetes and obesity to see how many achieve a target blood sugar level.

Status Withdrawn Stopped before any participant enrolled.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Who can join all sexes

Timeline Started 2022-10 · est. completion 2025-08

What this study is testing ClinicalTrials.gov NCT05444153 ↗

Description as written by the study sponsor.

This study compares the medicines semaglutide and empagliflozin in people with newly diagnosed type 2 diabetes and obesity. The study will look mainly at how well the blood sugar and body weight are controlled when participants are taking the study medicine. Participants will either get semaglutide tablets or empagliflozin tablets. Which treatment participants get is decided by chance. Participants will get one tablet per day for 2 years. The study will last for about 2 years and 8 weeks.

Treatments tested

Semaglutide Drug

Participants will receive 1 tablet of oral semaglutide once daily.
Empagliflozin Drug

Participants will receive 1 tablet of empagliflozin once daily.

Main thing measured	Participants acheiving glycated haemoglobin (HbA1c) less than (<) 7 percentage (%) (Yes/No)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05444153 ↗